Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maxacalcitol - Chugai Pharmaceutical

Drug Profile

Maxacalcitol - Chugai Pharmaceutical

Alternative Names: 22-oxacalcitriol; OCT; Oxarol

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Maruho
  • Class Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols; Skin disorder therapies
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Ichthyosis; Palmoplantar keratoderma; Palmoplantar pustulosis; Psoriasis; Secondary hyperparathyroidism

Most Recent Events

  • 01 Dec 2019 Chugai Pharmaceutical completes transfer of rights for maxacalcitol to Maruho in Japan
  • 30 Jan 2019 Chugai Pharmaceutical plans to transfer rights for Maxacalcitol to Maruho from December 1, 2019
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Secondary-hyperparathyroidism(In volunteers) in Taiwan (IV, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top